⌘K
t
| Date | 31 Oct 2024 |
| Time | 14:10:01 |
| Category | AGMs and other meetings |
| ID | 4622K |
Renalytix plc
("Renalytix" or the "Company")
Result of General Meeting
LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, at the General Meeting ("GM") held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in the Circular that contains the Notice of General Meeting, which was sent to the Company's shareholders on 11 October 2024.
The results of the GM are detailed below:
|
|
In favour |
|
|
Against |
|
|
Withheld |
|
Resolution |
Votes |
% |
|
Votes |
% |
|
Votes |
|
1 |
101,692,587 |
98.73 |
|
1,311,467 |
1.27 |
|
41,789 |
|
2 |
102,375,306 |
99.85 |
|
157,078 |
0.15 |
|
513,459 |
|
3 |
101,675,617 |
98.71 |
|
1,326,507 |
1.29 |
|
43,719 |
For further information, please contact:
|
Renalytix Plc James McCullough, CEO
|
Via Walbrook PR |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) Nicholas Moore / Nick Harland / Ben Good
|
Tel: 020 7710 7600
|
|
|
Oberon Capital (Joint Broker and Sole Bookrunner) Mike Seabrook / Nick Lovering / Jessica Cave
|
Tel: 020 3179 5300
|
|
|
Walbrook PR Limited Alice Woodings |
Tel: 020 7933 8780 or renalytix@walbrookpr.com Mob: 07407 804 654
|
|
|
CapComm Partners Peter DeNardo |
Tel: 415-389-6400 or investors@renalytix.com
|
|
The person responsible for making this Announcement on behalf of the Company is
James McCullough, Chief Executive Officer.
About Renalytix plc
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.